This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (41)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Immunologic Disorders  • Multiple Sclerosis/ Demyelinating Disease  • Psychiatry  • Depression  • Alert me on articles by topic

David C. Mohr, PhD; Donald E. Goodkin, MD; Janeen Islar, BS; Stephen L. Hauser, MD; Claude P. Genain, MD

Arch Neurol. 2001;58:1081-1086.

Objective  To examine the relationship between depression, treatment of depression, and interferon gamma (IFN-) production by peripheral blood mononuclear cells in patients with comorbid diagnoses of relapsing-remitting multiple sclerosis (MS) and major depressive disorder.

Design  A randomized comparative outcome trial of three 16-week treatments for depression. Assessments were conducted at baseline, week 8, and treatment cessation.

Setting  An academic outpatient treatment and clinical research center.

Patients  Fourteen patients who met the criteria for relapsing-remitting MS and major depressive disorder.

Interventions  Individual cognitive behavioral therapy, group psychotherapy, or sertraline therapy.

Main Outcome Measures  Depression was assessed using the Beck Depression Inventory. Interferon gamma production by peripheral blood mononuclear cells was measured following stimulation with OKT3 or recombinant human myelin oligodendrocyte glycoprotein (MOG). Variability in immune assays was controlled using 8 nondepressed healthy subjects who were enrolled at times corresponding with the enrollment of MS patients.

Results  Results of the Beck Depression Inventory were significantly related to IFN- production stimulated with OKT3 or MOG at baseline (P.03 for all). Level of depression, OKT3-stimulated IFN- production, and MOG-stimulated IFN- production all declined significantly over the 16-week treatment period (P.03 for all). Among controls, there were no significant changes over time in OKT3- or MOG-stimulated IFN-, or in depression (P.25 for all).

Conclusions  These findings suggest that the production of the proinflammatory cytokine IFN- by autoaggressive T cells in relapsing-remitting MS is related to depression and that treatment of depression may decrease IFN- production. Thus, treatment of depression may provide a novel disease-modifying therapeutic strategy as well as a symptomatic treatment for patients with MS.

From the Departments of Psychiatry (Dr Mohr) and Neurology (Drs Mohr, Goodkin, Hauser, and Genain and Ms Islar), University of California, San Francisco.

Corresponding author and reprints: David C. Mohr, PhD, Veterans Affairs Medical Center (116-A), 4150 Clement St, San Francisco, CA 94121 (e-mail: dmohr{at}itsa.ucsf.edu).

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2001;58(7):1172-1174.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Influence of Positive Experiences on Depression and Quality of Life in Persons With Multiple Sclerosis
Phillips and Stuifbergen
J Holist Nurs 2008;26:41-48.
ABSTRACT  

Review: Brain immune communication psychoneuroimmunology of multiple sclerosis
Kern and Ziemssen
Mult Scler 2008;14:6-21.
ABSTRACT  

Antidepressant use in multiple sclerosis: epidemiologic study of a large community sample
Cetin et al.
Mult Scler 2007;13:1046-1053.
ABSTRACT  

Screening for depression among patients with multiple sclerosis: two questions may be enough
Mohr et al.
Mult Scler 2007;13:215-219.
ABSTRACT  

The Goldman Consensus statement on depression in multiple sclerosis
Goldman Consensus Group
Mult Scler 2005;11:328-337.
ABSTRACT  

Altered cytokine responses to cognitive stress in multiple sclerosis patients with fatigue
Heesen et al.
Mult Scler 2005;11:51-57.
ABSTRACT  

Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis
Mohr et al.
BMJ 2004;328:731.
ABSTRACT | FULL TEXT  

Psychological Theories of Depression: Potential Application for the Prevention of Acute Coronary Syndrome Recurrence
Davidson et al.
Psychosom. Med. 2004;66:165-173.
ABSTRACT | FULL TEXT  

Effects of Treatment for Depression on Fatigue in Multiple Sclerosis
Mohr et al.
Psychosom. Med. 2003;65:542-547.
ABSTRACT | FULL TEXT  

Multiple sclerosis and depression: influence of interferon b therapy
Zephir et al.
Mult Scler 2003;9:284-288.
ABSTRACT  

Comparative assessment of Yale Single Q uestion and Beck Depression Inventory Scale in screening for depression in multiple sclerosis
Avasarala et al.
Mult Scler 2003;9:307-310.
ABSTRACT  

Cytokines in Depression and Heart Failure
Pasic et al.
Psychosom. Med. 2003;65:181-193.
ABSTRACT | FULL TEXT  

Moderating Effects of Coping on the Relationship Between Stress and the Development of New Brain Lesions in Multiple Sclerosis
Mohr et al.
Psychosom. Med. 2002;64:803-809.
ABSTRACT | FULL TEXT  

Multiple Sclerosis, Depression, and the Immune System
JWatch Psychiatry 2001;2001:2-2.
FULL TEXT